Antibiotics do not lower Avastin infection risk

Article

The incidence of endophthalmitis is independent of whether prophylactic antibiotics are administered in conjunction with Avastin (bevacizumab) injections, according to results of a study published in the February 2008 issue of Spektrum der Augenheilkunde.

Prophylactic antibiotics do not lower the incidence of endophthalmitis in patients receiving Avastin (bevacizumab) injections, according to results of a study published in the February 2008 issue of Spektrum der Augenheilkunde.

Carsten H. Meyer, MD of the Augenklinik at Bonn University, Germany and colleagues conducted a retrospective study of two groups of patients receiving 1.25 mg/0.05 ml Avastin after an incubation of 5% povidone-iodine for 60 seconds in the conjunctival fornix. The first set of subjects (Group A; n=984) underwent the injection as an outpatient procedure and received no prophylactic antibiotics after the injection. In the second set (Group B; n=860), patients were admitted to hospital for one day and received three days of topical antibiotics following the injection.

The subjects of Group A had a zero incidence of post-injection endophthalmitis; two patients developed intraocular uveitis, which was treated successfully with topical steroids. In Group B, the two cases of post-injection endophthalmitis that developed after five days were treated with vitrectomy.

The researchers concluded that administration of prophylactic antibiotics was unable to eliminate endophthalmitis in these cases; when considering this factor, it is irrelevant whether the injection of Avastin is administered on an inpatient or outpatient basis.

Newsletter

Get the essential updates shaping the future of pharma manufacturing and compliance—subscribe today to Pharmaceutical Technology and never miss a breakthrough.

Recent Videos
Jay Chhablani, MD, shares late-breaking data from the ArMaDa trial, investigating gene therapy for Geographic Atrophy and dry age-related macular degeneration, at EURETINA
Editorial advisory board member Alexandra Miere, MD, PhD, speaks about the ACTOR and HERMES studies at the 2025 European Society of Retina Specialists (EURETINA) Congress
María Berrocal, MD, speaks about the Vit-Buckle Society symposium hosted at the 2025 European Society of Retina Specialists (EURETINA) annual meeting
© 2025 MJH Life Sciences

All rights reserved.